688428 诺诚健华
已收盘 02-05 15:00:00
资讯
新帖
简况
港股异动 | 诺诚健华(09969)早盘涨超4% 公司首次实现扭亏为盈 核心产品奥布替尼贡献显著增量
智通财经 · 10:50
港股异动 | 诺诚健华(09969)早盘涨超4% 公司首次实现扭亏为盈 核心产品奥布替尼贡献显著增量
诺诚健华（688428）披露证券变动月报表，2月4日股价上涨1.8%
证券之星 · 02-04 22:26
诺诚健华（688428）披露证券变动月报表，2月4日股价上涨1.8%
诺诚健华：公司预计2025年度首次实现扭亏为盈
证券日报 · 02-04 21:38
诺诚健华：公司预计2025年度首次实现扭亏为盈
诺诚健华新型TYK2抑制剂ICP-488治疗银屑病的III期临床试验完成患者入组
每日经济新闻 · 02-02
诺诚健华新型TYK2抑制剂ICP-488治疗银屑病的III期临床试验完成患者入组
每周股票复盘：诺诚健华（688428）预计2025年净利6.33亿
证券之星 · 02-01
每周股票复盘：诺诚健华（688428）预计2025年净利6.33亿
诺诚健华(09969.HK)高开逾13%
每日经济新闻 · 01-30
诺诚健华(09969.HK)高开逾13%
股市必读：诺诚健华（688428）预计2025年全年扣非后净利润盈利约5.34亿元
中金财经 · 01-30
股市必读：诺诚健华（688428）预计2025年全年扣非后净利润盈利约5.34亿元
诺诚健华（688428）披露2025年年度业绩预告，1月29日股价下跌1.18%
证券之星 · 01-29
诺诚健华（688428）披露2025年年度业绩预告，1月29日股价下跌1.18%
诺诚健华：公司未来会持续推进全球化战略
证券日报 · 01-29
诺诚健华：公司未来会持续推进全球化战略
诺诚健华：二级市场股价受多种因素影响
证券日报 · 01-29
诺诚健华：二级市场股价受多种因素影响
诺诚健华：预计2025年年度净利润6.33亿元 同比扭亏为盈
每日经济新闻 · 01-29
诺诚健华：预计2025年年度净利润6.33亿元 同比扭亏为盈
诺诚健华：截至2026年1月9日公司A股股东户数约为1.93万户
证券日报 · 01-16
诺诚健华：截至2026年1月9日公司A股股东户数约为1.93万户
每周股票复盘：诺诚健华（688428）股本无变动，两股权激励计划剩余可授出股份共1417.645万股
证券之星 · 01-11
每周股票复盘：诺诚健华（688428）股本无变动，两股权激励计划剩余可授出股份共1417.645万股
诺诚健华：公司营业收入2025年前三季度实现加速增长
证券日报 · 01-07
诺诚健华：公司营业收入2025年前三季度实现加速增长
诺诚健华（688428）披露证券变动月报表，1月6日股价下跌2.65%
证券之星 · 01-06
诺诚健华（688428）披露证券变动月报表，1月6日股价下跌2.65%
诺诚健华新型TYK2抑制剂Soficitinib治疗特应性皮炎III期注册临床研究完成患者入组
人民财讯 · 01-02
诺诚健华新型TYK2抑制剂Soficitinib治疗特应性皮炎III期注册临床研究完成患者入组
每周股票复盘：诺诚健华（688428）授出140万份受限制股份单位
证券之星 · 01-02
每周股票复盘：诺诚健华（688428）授出140万份受限制股份单位
打卡北京小巨人｜诺诚健华总监：中国创新药几乎成为世界创新名片
新京报 · 2025-12-31
打卡北京小巨人｜诺诚健华总监：中国创新药几乎成为世界创新名片
诺诚健华(09969)授出140万份受限制股份单位
智通财经 · 2025-12-31
诺诚健华(09969)授出140万份受限制股份单位
光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事
时代周报 · 2025-12-25
光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事
加载更多
公司概况
公司名称：
诺诚健华医药有限公司
所属行业：
医药制造业
上市日期：
2022-09-21
主营业务：
诺诚健华医药有限公司的主营业务是创新药的研发、生产及商业化。公司的主要产品是奥布替尼、坦昔妥单抗、ICP-248、ICP-B02。公司2023年被认定为国家级专精特新“小巨人”企业。
发行价格：
11.03
{"stockData":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":21.81,"timestamp":1770274800000,"preClose":21.51,"halted":0,"volume":9705223,"delay":0,"changeRate":0.0139,"floatShares":268000000,"shares":1764999999,"eps":-0.1302,"marketStatus":"已收盘","change":0.3,"latestTime":"02-05 15:00:00","open":21.57,"high":22.12,"low":21.32,"amount":212000000,"amplitude":0.0372,"askPrice":21.81,"askSize":116,"bidPrice":21.8,"bidSize":70,"shortable":0,"etf":0,"ttmEps":-0.1302,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770341400000},"marketStatusCode":5,"adr":0,"adjPreClose":21.51,"symbolType":"stock_kcb","openAndCloseTimeList":[[1770255000000,1770262200000],[1770267600000,1770274800000]],"highLimit":23.66,"lowLimit":19.36,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1764643952,"isCdr":false,"pbRate":5.77,"roa":"--","roe":"--","epsLYR":-0.26,"committee":-0.130527,"marketValue":38487000000,"turnoverRate":0.0362,"status":0,"afterMarket":{"amount":0,"volume":0,"close":21.81,"buyVolume":0,"sellVolume":0,"time":1770276837558,"indexStatus":"已收盘 02-05 15:30:00","preClose":21.51},"hkstockBrief":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":11.84,"timestamp":1770278908006,"preClose":11.38,"halted":0,"volume":7714028,"delay":0,"premium":"-51.77"},"floatMarketCap":5853000000},"requestUrl":"/m/hq/s/688428","defaultTab":"news","newsList":[{"id":"2609346495","title":"港股异动 | 诺诚健华(09969)早盘涨超4% 公司首次实现扭亏为盈 核心产品奥布替尼贡献显著增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2609346495","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609346495?lang=zh_cn&edition=full","pubTime":"2026-02-05 10:50","pubTimestamp":1770259821,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺诚健华早盘涨超4%，截至发稿，涨3.95%，报11.83港元，成交额3869.91万港元。消息面上，诺诚健华此前发布业绩预告，预计2025年实现收入23.7亿元，同比增长约134%；预计2025年归母净利润首次扭亏为盈，达6.3亿元左右。核心产品奥布替尼贡献显著增量，2025年5月坦昔妥单抗获批上市后进一步丰富药品收入来源。值得注意的是，诺诚健华宣布，公司自主研发的新型TYK2抑制剂ICP-488治疗银屑病的III期临床试验已完成患者入组，总共入组383例患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401913.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4585","VXUS","688428","VT","BK4588","BK0239","BK1574","09969"],"gpt_icon":0},{"id":"2608398843","title":"诺诚健华（688428）披露证券变动月报表，2月4日股价上涨1.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608398843","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608398843?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:26","pubTimestamp":1770215179,"startTime":"0","endTime":"0","summary":"截至2026年2月4日收盘，诺诚健华报收于21.51元，较前一交易日上涨1.8%，最新总市值为379.57亿元。该股当日开盘21.06元，最高21.72元，最低20.9元，成交额达1.91亿元，换手率为3.34%。近日，诺诚健华医药有限公司发布证券变动月报表。公司确认已符合香港联交所规定的公众持股量要求。此外，公告提及2023年及2024年人民币股份激励计划的相关安排，涉及部分限制性股票失效情况，但本月未因相关协议导致股份变动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400041567.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1574","BK0239","688428","161027","09969"],"gpt_icon":0},{"id":"2608036200","title":"诺诚健华：公司预计2025年度首次实现扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2608036200","media":"证券日报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608036200?lang=zh_cn&edition=full","pubTime":"2026-02-04 21:38","pubTimestamp":1770212317,"startTime":"0","endTime":"0","summary":"证券日报网讯2月4日，诺诚健华在互动平台回答投资者提问时表示，公司在管线推进、商业化拓展等方面均按照计划及目标顺利推进，经营一切正常，不存在经营困境。根据公司业绩预告，公司预计2025年度首次实现扭亏为盈，预计2025年实现营业总收入人民币23.65亿元左右，与上年同期相比增长134%左右，归属于母公司所有者的净利润为6.33亿元左右。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602043641731339.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688428","09969","BK1574","BK0239","BK1161"],"gpt_icon":0},{"id":"2608880406","title":"诺诚健华新型TYK2抑制剂ICP-488治疗银屑病的III期临床试验完成患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2608880406","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608880406?lang=zh_cn&edition=full","pubTime":"2026-02-02 08:50","pubTimestamp":1769993437,"startTime":"0","endTime":"0","summary":"每经AI快讯，2月2日，诺诚健华官微宣布，公司自主研发的新型TYK2抑制剂ICP-488治疗银屑病的III期临床试验已完成患者入组，总共入组383例患者。这一里程碑标志着ICP-488治疗银屑病取得重大临床进展，有望为银屑病患者带来新的口服治疗选择。这项临床试验为多中心、随机、双盲、安慰剂对照，旨在评价ICP-488单药治疗中重度斑块状银屑病成人患者的有效性和安全性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602023638037294.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602023638037294.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09969","BK1574","BK1161","688428","BK4134","BK0239","III"],"gpt_icon":0},{"id":"2608072758","title":"每周股票复盘：诺诚健华（688428）预计2025年净利6.33亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2608072758","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608072758?lang=zh_cn&edition=full","pubTime":"2026-02-01 01:55","pubTimestamp":1769882111,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，诺诚健华报收于21.4元，较上周的20.29元上涨5.47%。本周，诺诚健华1月30日盘中最高价报22.5元。诺诚健华当前最新总市值377.63亿元，在化学制药板块市值排名12/150，在两市A股市值排名553/5184。业绩披露要点诺诚健华发布业绩预告，预计2025年全年归属净利润盈利约6.33亿元。公司公告汇总诺诚健华医药有限公司预计2025年实现营业总收入约23.65亿元，同比增长134%左右。扣除非经常性损益后的净利润为5.34亿元左右，同比增加9.74亿元左右。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100000402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0239","BK1161","09969","688428"],"gpt_icon":0},{"id":"2607628066","title":"诺诚健华(09969.HK)高开逾13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607628066","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607628066?lang=zh_cn&edition=full","pubTime":"2026-01-30 09:36","pubTimestamp":1769736987,"startTime":"0","endTime":"0","summary":"每经AI快讯，诺诚健华(09969.HK)高开逾13%，截至发稿，涨13.6%，报13.2港元，成交额1099.56万港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601303636358961.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601303636358961.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688428","BK1574","BK1161","09969","BK0239"],"gpt_icon":0},{"id":"2607050701","title":"股市必读：诺诚健华（688428）预计2025年全年扣非后净利润盈利约5.34亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607050701","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607050701?lang=zh_cn&edition=full","pubTime":"2026-01-30 08:06","pubTimestamp":1769731601,"startTime":"0","endTime":"0","summary":"业绩预告诺诚健华发布业绩预告，预计2025年全年扣非后净利润盈利约5.34亿元；预计2025年全年归属净利润盈利约6.33亿元。诺诚健华医药有限公司2025年年度业绩预告诺诚健华医药有限公司预计2025年实现营业总收入约23.65亿元，同比增长134%左右；预计2025年度归属于母公司所有者的净利润为6.33亿元左右，同比增加10.74亿元左右，首次实现扭亏为盈；扣除非经常性损益后的净利润为5.34亿元左右，同比增加9.74亿元左右。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260130/31984716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688428","09969"],"gpt_icon":0},{"id":"2607361810","title":"诺诚健华（688428）披露2025年年度业绩预告，1月29日股价下跌1.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607361810","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607361810?lang=zh_cn&edition=full","pubTime":"2026-01-29 22:57","pubTimestamp":1769698630,"startTime":"0","endTime":"0","summary":"截至2026年1月29日收盘，诺诚健华报收于20.15元，较前一交易日下跌1.18%，最新总市值为355.58亿元。该股当日开盘20.35元，最高20.74元，最低19.96元，成交额达1.31亿元，换手率为2.41%。近日，诺诚健华医药有限公司发布2025年年度业绩预告。本次业绩预告未经注册会计师审计。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900044032.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","09969","BK1161","BK1574","BK0239"],"gpt_icon":0},{"id":"2607384830","title":"诺诚健华：公司未来会持续推进全球化战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2607384830","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607384830?lang=zh_cn&edition=full","pubTime":"2026-01-29 21:50","pubTimestamp":1769694643,"startTime":"0","endTime":"0","summary":"证券日报网讯1月29日，诺诚健华在互动平台回答投资者提问时表示，公司与Zenas交易不仅为公司带来了实质性的即期财务收益，进一步增强了公司的现金储备与资产结构，里程碑付款可以为公司带来可持续的现金流与长期收益，此次合作也将有助于最大化奥布替尼在全球范围内的临床与商业价值，使产品能够更快惠及全球患者，也充分体现了公司创新资产的国际竞争力与长期商业潜力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601293635632811.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09969","688428","BK1161","BK0239","BK1574"],"gpt_icon":0},{"id":"2607038418","title":"诺诚健华：二级市场股价受多种因素影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2607038418","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607038418?lang=zh_cn&edition=full","pubTime":"2026-01-29 21:50","pubTimestamp":1769694642,"startTime":"0","endTime":"0","summary":"诺诚健华：二级市场股价受多种因素影响","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601293635632188.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","09969","688428","BK1161","BK0239"],"gpt_icon":0},{"id":"2607704567","title":"诺诚健华：预计2025年年度净利润6.33亿元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2607704567","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607704567?lang=zh_cn&edition=full","pubTime":"2026-01-29 16:40","pubTimestamp":1769676015,"startTime":"0","endTime":"0","summary":"每经AI快讯，1月29日，诺诚健华公告，公司预计2025年度首次实现扭亏为盈，归属于母公司所有者的净利润为6.33亿元左右，上年同期为亏损4.41亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601293635268968.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601293635268968.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688428","09969"],"gpt_icon":0},{"id":"2603937669","title":"诺诚健华：截至2026年1月9日公司A股股东户数约为1.93万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2603937669","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603937669?lang=zh_cn&edition=full","pubTime":"2026-01-16 20:12","pubTimestamp":1768565522,"startTime":"0","endTime":"0","summary":"证券日报网讯1月16日，诺诚健华在互动平台回答投资者提问时表示，截至2026年1月9日公司A股股东户数约为1.93万户。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601163622112851.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","688428","BK1161","09969","159982","399300","BK1574"],"gpt_icon":0},{"id":"2602553569","title":"每周股票复盘：诺诚健华（688428）股本无变动，两股权激励计划剩余可授出股份共1417.645万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2602553569","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602553569?lang=zh_cn&edition=full","pubTime":"2026-01-11 02:40","pubTimestamp":1768070417,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，诺诚健华报收于22.57元，较上周的20.52元上涨9.99%。本周，诺诚健华1月9日盘中最高价报22.85元。本周关注点公司公告汇总：截至2025年12月31日，诺诚健华总股本未变，已发行股份无增减。公司公告汇总：2023年及2024年人民币股激励计划合计剩余可授出14,176,450股。已发行股份总数无变动，其中港股上市股份为1,496,284,235股，包括1,493,798,235股已发行股份和2,486,000股库存股；科创板上市人民币股份为268,359,717股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","BK1574","09969","BK1161","BK0239"],"gpt_icon":0},{"id":"2601806825","title":"诺诚健华：公司营业收入2025年前三季度实现加速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2601806825","media":"证券日报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601806825?lang=zh_cn&edition=full","pubTime":"2026-01-07 21:36","pubTimestamp":1767792974,"startTime":"0","endTime":"0","summary":"证券日报网讯1月7日，诺诚健华在互动平台回答投资者提问时表示，公司营业收入2025年前三季度实现加速增长，公司对全年业绩目标的达成充满信心，全年业绩请关注公司按期披露的业绩预告及定期报告。二级市场股价受多种因素影响，请您注意投资风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601073611756388.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09969","688428"],"gpt_icon":0},{"id":"2601139718","title":"诺诚健华（688428）披露证券变动月报表，1月6日股价下跌2.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601139718","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601139718?lang=zh_cn&edition=full","pubTime":"2026-01-06 22:20","pubTimestamp":1767709235,"startTime":"0","endTime":"0","summary":"截至2026年1月6日收盘，诺诚健华报收于20.92元，较前一交易日下跌2.65%，最新总市值为369.16亿元。公司近日发布公告，披露截至2025年12月31日的证券变动月报表。已发行股份总数无变动，其中港股上市股份为1,496,284,235股，包括1,493,798,235股已发行股份和2,486,000股库存股；科创板上市人民币股份为268,359,717股。公司存在两项股权激励计划：2023年人民币股激励计划剩余可授出4,531,250股，2024年人民币股激励计划剩余可授出9,645,200股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600042473.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","161027","688428","BK0239","BK1574","BK1161"],"gpt_icon":0},{"id":"2600037932","title":"诺诚健华新型TYK2抑制剂Soficitinib治疗特应性皮炎III期注册临床研究完成患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2600037932","media":"人民财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600037932?lang=zh_cn&edition=full","pubTime":"2026-01-02 09:22","pubTimestamp":1767316966,"startTime":"0","endTime":"0","summary":"【诺诚健华新型TYK2抑制剂Soficitinib治疗特应性皮炎III期注册临床研究完成患者入组】诺诚健华今日宣布，公司自主研发的新型TYK2抑制剂soficitinib（ICP-332）的临床研究获得重大进展，治疗中重度特应性皮炎（AD）的III期注册临床试验已完成患者入组，标志着soficitinib解决AD疾病迈出了关键一步。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601023607534023.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09969","BK1574","688428","BK1161","BK0239","III","BK4134"],"gpt_icon":0},{"id":"2600039998","title":"每周股票复盘：诺诚健华（688428）授出140万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2600039998","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600039998?lang=zh_cn&edition=full","pubTime":"2026-01-02 04:05","pubTimestamp":1767297912,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，诺诚健华报收于21.44元，较上周的22.2元下跌3.42%。本周，诺诚健华12月23日盘中最高价报22.67元。诺诚健华当前最新总市值362.1亿元，在化学制药板块市值排名12/150，在两市A股市值排名527/5181。本周关注点公司公告汇总：诺诚健华根据2023年股权激励计划授出合计1,400,000份受限制股份单位。公司公告汇总诺诚健华医药有限公司于2025年12月31日根据2023年股权激励计划授予两名雇员参与者合计1,400,000份受限制股份单位，约占公司已发行股份总数的0.08%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200001207.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","BK1574","BK0239","BK1161","688428"],"gpt_icon":0},{"id":"2595705107","title":"打卡北京小巨人｜诺诚健华总监：中国创新药几乎成为世界创新名片","url":"https://stock-news.laohu8.com/highlight/detail?id=2595705107","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595705107?lang=zh_cn&edition=full","pubTime":"2025-12-31 22:59","pubTimestamp":1767193140,"startTime":"0","endTime":"0","summary":"\n 诺诚健华企业传播执行总监陆春华表示：“中国创新药的知识产权授权给了国际的MNC公司，今年上半年的总的对外授权的总金额，已经达到了600亿美元，超过了2024年... [全文]\n","market":"sh","thumbnail":"https://media.bjnews.com.cn/cover/2025/12/31/5670566291698688769.jpeg?x-oss-process=image/resize,m_lfit,w_365","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/cover/2025/12/31/5670566291698688769.jpeg?x-oss-process=image/resize,m_lfit,w_365"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1767193147129723.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1767193147129723.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["BK0239","BK1574","06978","BK1161","09969","159992","688428"],"gpt_icon":0},{"id":"2595727116","title":"诺诚健华(09969)授出140万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2595727116","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595727116?lang=zh_cn&edition=full","pubTime":"2025-12-31 17:18","pubTimestamp":1767172702,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华(09969)发布公告，于2025年12月31日，公司根据2023年股权激励计划授予两名承授人140万份受限制股份单位，相当于公司于本公告日期已发行股份总数的约0.08%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387758.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK0239","688428","BK1574","09969"],"gpt_icon":0},{"id":"2594287939","title":"光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事","url":"https://stock-news.laohu8.com/highlight/detail?id=2594287939","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594287939?lang=zh_cn&edition=full","pubTime":"2025-12-25 14:21","pubTimestamp":1766643688,"startTime":"0","endTime":"0","summary":"今年创新药企业频繁宣布BD交易，但从三季度以来，原本利好的消息却不被二级市场买账。最近一周，BD交易再掀一个小高潮。12月22日，先声药业（02096.HK）宣布其附属公司江苏再明与Ipsen于12月19日签订独家授权许可协议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512253601825588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2148510915.USD","01801","BK0196","02142","688331","LU0502904849.HKD","01530","LU0405327148.USD","LU2580892862.HKD","01167","BK0028","600276","000661","BK0057","BK1593","BK0012","LU1328615791.USD","LU1997245094.SGD","LU1969619763.USD","LU2495084118.USD","BK1589","603087","02096","BK0183","BK0239","LU1146622755.USD","02509","BK0188","688062","002755","06978","LU1064131003.USD","LU2097828474.EUR","688336","LU2097828557.USD","09995","LU1997245177.USD","LU1064130708.USD","LU2097828805.USD","LU0405327494.USD","BK0060","LU1781817850.SGD","LU2097828631.EUR","BK1574","LU2488822045.USD","LU2097828714.EUR","LU1997244956.HKD","BK1161","03692","688428"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770281604797,"stockEarnings":[{"period":"1week","weight":0.0549},{"period":"1month","weight":0.0009},{"period":"3month","weight":-0.1141},{"period":"6month","weight":-0.2474},{"period":"1year","weight":0.7704},{"period":"ytd","weight":0.0482}],"compareEarnings":[{"period":"1week","weight":-0.0118},{"period":"1month","weight":0.0196},{"period":"3month","weight":0.0236},{"period":"6month","weight":0.1285},{"period":"1year","weight":0.262},{"period":"ytd","weight":0.0336}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"诺诚健华医药有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"19600人(较上一季度增加1.55%)","perCapita":"13691股","listingDate":"2022-09-21","address":"Ogier Global(Cayman)Limited 89 Nexus Way Camana Bay Grand Cayma KY1-9009 Cayman Islands","registeredCapital":"0万元","survey":" 诺诚健华医药有限公司的主营业务是创新药的研发、生产及商业化。公司的主要产品是奥布替尼、坦昔妥单抗、ICP-248、ICP-B02。公司2023年被认定为国家级专精特新“小巨人”企业。","listedPrice":11.03},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(688428)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,688428,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(688428)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}